The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000412336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
15/02/2026
Date registered
Help: Date registered
2/04/2026
Date last updated
Help: Date last updated
2/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
2/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
MiSaver Cell Injection for Heart Attack : Safety and Efficacy Study of Cells derived from Umbilical Cord Blood
Scientific title
A Phase 2, Multi-country, Multi-center, Prospective, Single-blind, Randomized, Placebo-controlled, safety, efficacy, and Dose Finding Study of MiSaver (Umbilical Cord Blood Nucleated Cells) in Subjects with Acute Myocardial Infarction.
Additional trial identifiers [1] 316541 0
Nil known
Universal Trial Number (UTN)
U1111-1318-9786
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Acute Myocardial Infarction 340691 0
Condition category
Condition code
Cardiovascular 336882 336882 0 0
Coronary heart disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a prospective, single-blind, randomized, placebo-controlled, parallel-group, multi-center, multi-region study evaluating the safety, efficacy, and dose response of MiSaver in subjects with acute myocardial infarction (AMI).
A total of 102 subjects will be enrolled across approximately 9 to 14 study sites (3–6 sites in Taiwan and 6–8 sites in Australia). Eligible subjects will be randomly assigned in a 1:1:1 ratio to one of the following three treatment arms:
1. MiSaver low-dose group: 0.5 × 10^7 total nucleated cells (TNC)/kg
2. MiSaver high-dose group: 1.6 × 10^7 total nucleated cells (TNC)/kg
3. Placebo control group: normal saline
MiSaver (a cell-based investigational product) or placebo (normal saline) will be administered as a single intracoronary infusion during the Treatment Phase, which occurs between 36 hours and 7 days following AMI diagnosis. The investigational product or placebo will be delivered once only (single administration) via standardized intracoronary infusion procedures across all study sites.
The study consists of three phases:
-Screening Phase: 0–36 hours post-AMI diagnosis
-Treatment Phase: Single administration between 36 hours and 7 days post-AMI diagnosis
-Follow-up Phase: 12 months after treatment
Each participant will be followed for approximately 1 year to assess safety and efficacy outcomes.
Efficacy Assessments and Procedures:
1. 2D Echocardiograms
2. Cardiac Magnetic Resonance Imaging
3. New York Heart Association Functional Classification
4. Canadian Cardiovascular Society Functional Classification of Angina Test
5. Kansas City Cardiomyopathy Questionnaire
6. Seattle Angina Questionnaire
7. Clinical Frailty Scale

Safety Assessments and Procedures:
1. Physical Examination
2. Body Weight and Height
3. Vital Signs
4. Electrocardiograms
5. Clinical Laboratory Assessments

Intervention code [1] 333215 0
Treatment: Other
Description of the comparator or control
Intervention Code: 7037 (Placebo)
Intervention Name: Normal saline
Description: Normal saline (0.9% sodium chloride) administered as a placebo control in a single intracoronary infusion during the Treatment Phase, between 36 hours and 7 days post-AMI diagnosis.
Control group
Placebo

Outcomes
Primary outcome [1] 344401 0
-Left Ventricular Ejection Fraction (LVEF): Change from baseline to Month 12 as a measure of left ventricular performance.
Timepoint [1] 344401 0
Month 12: Assessments will be made at 12 months after treatment (baseline to Month 12).
Primary outcome [2] 344580 0
-NYHA Functional Classification: Change from baseline to Month 12 as a measure of functional improvement.
Timepoint [2] 344580 0
Month 12: Assessments will be made at 12 months after treatment (baseline to Month 12).
Secondary outcome [1] 457815 0
NT-proBNP: The percent change and the absolute change from baseline to Month 12 for NT-proBNP, a biomarker used to assess heart failure severity. (“this will be assessed as a composite outcome”)
Timepoint [1] 457815 0
Baseline to Month 12: Change from baseline to 12 months post-treatment, with NT-proBNP levels measured at baseline and at Month 12.
Secondary outcome [2] 458430 0
-Left Ventricular End-Diastolic Volume (LVEDV) and Left Ventricular End-Diastolic Dimension (LV end-diastolic dimension)
Timepoint [2] 458430 0
Month 12: Assessments will be made at 12 months after treatment (baseline to Month 12).
Secondary outcome [3] 458431 0
-Left Ventricular End-Systolic Volume (LVESV) and Left Ventricular End-Systolic Dimension (LV end-systolic dimension)
Timepoint [3] 458431 0
Month 12: Assessments will be made at 12 months after treatment (baseline to Month 12).
Secondary outcome [4] 458432 0
-Left Atrial Dimension (LA dimension) and Left Atrial Volume (LA volume)
Timepoint [4] 458432 0
Month 12: Assessments will be made at 12 months after treatment (baseline to Month 12).
Secondary outcome [5] 458433 0
-Cardiovascular Mortality: The occurrence of death due to cardiovascular causes.
Timepoint [5] 458433 0
Up to 12 months: The time frame for assessing the occurrence of cardiovascular mortality, new MI, and non-fatal stroke, with evaluations conducted over the course of 12 months post-treatment.
Secondary outcome [6] 458434 0
-New Myocardial Infarction (MI): The occurrence of a new myocardial infarction.
Timepoint [6] 458434 0
Up to 12 months: The time frame for assessing the occurrence of cardiovascular mortality, new MI, and non-fatal stroke, with evaluations conducted over the course of 12 months post-treatment.
Secondary outcome [7] 458435 0
-Non-Fatal Stroke: The occurrence of a non-fatal stroke.
Timepoint [7] 458435 0
Up to 12 months: The time frame for assessing the occurrence of cardiovascular mortality, new MI, and non-fatal stroke, with evaluations conducted over the course of 12 months post-treatment.
Secondary outcome [8] 458436 0
-Kansas City Cardiomyopathy Questionnaire (KCCQ-12): Assessment of functional status and health-related quality of life in subjects with AMI.
Timepoint [8] 458436 0
Baseline to Month 12: Change from baseline to 12 months post-treatment, with measurements taken at baseline and at Month 12.
Secondary outcome [9] 458437 0
-Seattle Angina Questionnaire (SAQ-7): Evaluation of angina-related functional status and symptoms.
Timepoint [9] 458437 0
Baseline to Month 12: Change from baseline to 12 months post-treatment, with measurements taken at baseline and at Month 12.
Secondary outcome [10] 458438 0
-Clinical Frailty Scale: Measurement of frailty status to assess the functional capacity and frailty in AMI subjects.
Timepoint [10] 458438 0
Baseline to Month 12: Change from baseline to 12 months post-treatment, with measurements taken at baseline and at Month 12.
Secondary outcome [11] 458439 0
-CCS Classification: Classification of angina severity based on the Canadian Cardiovascular Society (CCS) angina scale.
Timepoint [11] 458439 0
Baseline to Month 12: Change from baseline to 12 months post-treatment, with measurements taken at baseline and at Month 12.
Secondary outcome [12] 458445 0
-Incidences of Adverse Events (AEs) and Serious Adverse Events (SAEs): The occurrence of adverse events and serious adverse events during the trial.
Timepoint [12] 458445 0
Throughout the study duration: The assessment of safety and tolerability will be ongoing throughout the trial, with data collected at key timepoints such as baseline, treatment phase, and follow-up. -AEs/SAEs: Continuously monitored throughout the trial.
Secondary outcome [13] 458447 0
-Incidences of Adverse Events of Special Interest (AESI): GVHD (Graft-Versus-Host Disease): The occurrence of GVHD, which is a potential complication in cell-based therapies.
Timepoint [13] 458447 0
Throughout the study duration: The assessment of safety and tolerability will be ongoing throughout the trial, with data collected at key timepoints such as baseline, treatment phase, and follow-up. -AESI (GVHD): Monitored throughout the trial based on symptoms and test results.
Secondary outcome [14] 458448 0
-Incidences of Major Adverse Cardiovascular Events (MACE): Including cardiovascular mortality, new myocardial infarction (MI), and non-fatal stroke.
Timepoint [14] 458448 0
Throughout the study duration: The assessment of safety and tolerability will be ongoing throughout the trial, with data collected at key timepoints such as baseline, treatment phase, and follow-up. -MACE: Evaluated continuously, with specific monitoring at follow-up visits.
Secondary outcome [15] 458451 0
-Incidences of Cardiovascular Mortality or Cardiovascular-Related Hospitalization: Including hospitalization for non-fatal MI, non-fatal stroke, or the management of heart failure.
Timepoint [15] 458451 0
Throughout the study duration: The assessment of safety and tolerability will be ongoing throughout the trial, with data collected at key timepoints such as baseline, treatment phase, and follow-up. -Cardiovascular Mortality or Hospitalization: Monitored throughout the trial.
Secondary outcome [16] 458453 0
-Clinically Significant Changes in Laboratory Tests: Assessment of clinical laboratory tests for any significant changes from baseline.
Timepoint [16] 458453 0
Throughout the study duration: The assessment of safety and tolerability will be ongoing throughout the trial, with data collected at key timepoints such as baseline, treatment phase, and follow-up. -Clinical Laboratory Tests, ECG, Vital Signs, Physical Examinations: Assessed at baseline and regular intervals throughout the study (e.g., at each visit, during the treatment phase, and at follow-up).
Secondary outcome [17] 458481 0
-Clinically Significant Changes in Vital Signs: Measurement of changes in vital signs (e.g., blood pressure, heart rate) from baseline.
Timepoint [17] 458481 0
Throughout the study duration: The assessment of safety and tolerability will be ongoing throughout the trial, with data collected at key timepoints such as baseline, treatment phase, and follow-up. -Clinical Laboratory Tests, ECG, Vital Signs, Physical Examinations: Assessed at baseline and regular intervals throughout the study (e.g., at each visit, during the treatment phase, and at follow-up).
Secondary outcome [18] 458482 0
-Clinically Significant Changes in Physical Examinations: Any significant findings during physical examination.
Timepoint [18] 458482 0
Throughout the study duration: The assessment of safety and tolerability will be ongoing throughout the trial, with data collected at key timepoints such as baseline, treatment phase, and follow-up. -Clinical Laboratory Tests, ECG, Vital Signs, Physical Examinations: Assessed at baseline and regular intervals throughout the study (e.g., at each visit, during the treatment phase, and at follow-up).

Eligibility
Key inclusion criteria
-Age and BMI:
Participants aged 45 years or older
Body Mass Index (BMI) less than or equal to 32
-Diagnosis of Acute Myocardial Infarction (AMI): Includes both ST-Elevation Myocardial Infarction (STEMI) (whether or not primary PCI has been performed) and Non-ST-Elevation Myocardial Infarction (NSTEMI), diagnosed by a cardiologist within 36 hours post-AMI.
-Timing for Cell Infusion: Patients must be able to initiate cell infusion within 36 hours to 7 days post-AMI diagnosis.
-LVEF less than or equal to 45%: Left ventricular ejection fraction (LVEF) less than or equal to 45%, as assessed by 2D echocardiogram.
-Hemodynamically Stable: Patients must be hemodynamically stable, requiring no vasopressor support in the past 24 hours.
Minimum age
45 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Women planning to conceive, currently pregnant, or breastfeeding.
2. Immunodeficiency disorders caused by infection, such as human immunodeficiency virus (HIV).
3. Requiring CABG or likely to need coronary revascularization within the next 12 months.
4. Severe aortic or mitral valve stenosis.
5. Life-threatening arrhythmias.
6. Active or recent malignancy. Note: Patients with active malignancy or malignancy
diagnosed within the past 5 years are excluded.
7. Hematologic disorders or other severe organ diseases with an expected survival of
less than one year.
8. Chronic kidney disease (eGFR less than 30 mL/min/1.73m²) or patients undergoing dialysis.
9. Subjects with autoimmune diseases or those who have already received
immunotherapy.
10. History of transfusion reactions.
11. Recipients of bone marrow or organ transplants.
12. Liver dysfunction, defined as a bilirubin level greater than 2.5 mg/dL or ALT and AST levels greater than five times the upper limit of normal (ULN).
13. Subjects who have previously received growth factors, cytokines, gene therapy, or stem cell therapy.
14. Current or previous participation in another study with investigational medicinal product within 90 days.
15. The Investigator is of the opinion the subject should not participate in the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The primary analysis of change from Baseline to Month 12 will be analyzed using an analysis
of covariance (ANCOVA) model with baseline LVEF as covariate and treatment as fixed effect. The adjusted mean and its 95% CI will be presented for each tre atment group comparison of MiSaver with placebo.
For the NYHA classification data, comparisons between the treatment groups will be made using linear regression models for continuous outcomes and the Wilcoxon rank-sum test for
changes in NYHA classi?cation.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment outside Australia
Country [1] 27831 0
Taiwan, Province Of China
State/province [1] 27831 0

Funding & Sponsors
Funding source category [1] 321157 0
Commercial sector/Industry
Name [1] 321157 0
HONYA Medical Co Ltd
Country [1] 321157 0
Taiwan, Province Of China
Funding source category [2] 321159 0
Commercial sector/Industry
Name [2] 321159 0
AUMed Pty Ltd
Country [2] 321159 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
HONYA Medical Co Ltd
Address
Country
Taiwan, Province Of China
Secondary sponsor category [1] 323867 0
Commercial sector/Industry
Name [1] 323867 0
AUMed Pty Ltd
Address [1] 323867 0
Country [1] 323867 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319688 0
The Institutional Review Board Chung Shan Medical University Hospital
Ethics committee address [1] 319688 0
Ethics committee country [1] 319688 0
Taiwan, Province Of China
Date submitted for ethics approval [1] 319688 0
25/10/2024
Approval date [1] 319688 0
08/11/2024
Ethics approval number [1] 319688 0
CS1-24127
Ethics committee name [2] 319690 0
MacKay Memorial Hospital Institutional Review Board
Ethics committee address [2] 319690 0
Ethics committee country [2] 319690 0
Taiwan, Province Of China
Date submitted for ethics approval [2] 319690 0
23/12/2024
Approval date [2] 319690 0
16/01/2025
Ethics approval number [2] 319690 0
24CT053Ae
Ethics committee name [3] 319691 0
Kaohsiung Medical University Chung-Ho Memorial Hospital Institutional Review Board
Ethics committee address [3] 319691 0
Ethics committee country [3] 319691 0
Taiwan, Province Of China
Date submitted for ethics approval [3] 319691 0
14/02/2025
Approval date [3] 319691 0
14/02/2025
Ethics approval number [3] 319691 0
KMUHIRB-F(I)-20250025

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148106 0
Prof Joseph Selvanayagam
Address 148106 0
Health and Medical Research Building GPO Box 2100, ADELAIDE, SA, 5001
Country 148106 0
Australia
Phone 148106 0
+61291910640
Fax 148106 0
Email 148106 0
Contact person for public queries
Name 148107 0
Dr. Robert Lin
Address 148107 0
Greenlight Clinical Pty Ltd/Suite 4 level 8/187 Macquarie St, Sydney NSW 2000
Country 148107 0
Australia
Phone 148107 0
+61 2 9191 0640
Fax 148107 0
Email 148107 0
Contact person for scientific queries
Name 148108 0
Dr. Robert Lin
Address 148108 0
Greenlight Clinical Pty Ltd/Suite 4 level 8/187 Macquarie St, Sydney NSW 2000
Country 148108 0
Australia
Phone 148108 0
+61 2 9191 0640
Fax 148108 0
Email 148108 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.